Van ECK Associates Corp decreased its position in Iqvia Holdings Inc (NYSE:IQV) by 11.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 179,205 shares of the medical research company’s stock after selling 23,110 shares during the quarter. Van ECK Associates Corp owned 0.09% of Iqvia worth $17,888,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Argent Trust Co purchased a new position in shares of Iqvia in the 4th quarter valued at about $1,410,000. Commerzbank Aktiengesellschaft FI purchased a new position in shares of Iqvia in the 1st quarter valued at about $306,000. Atria Investments LLC increased its stake in shares of Iqvia by 90.0% in the 1st quarter. Atria Investments LLC now owns 4,236 shares of the medical research company’s stock valued at $416,000 after purchasing an additional 2,006 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Iqvia by 1,144.6% in the 1st quarter. Victory Capital Management Inc. now owns 33,554 shares of the medical research company’s stock valued at $3,292,000 after purchasing an additional 30,858 shares in the last quarter. Finally, Comerica Securities Inc. purchased a new position in shares of Iqvia in the 1st quarter valued at about $1,815,000. 91.98% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on the company. Barclays restated an “overweight” rating and issued a $130.00 price target (up previously from $120.00) on shares of Iqvia in a research note on Wednesday, July 25th. Stifel Nicolaus lifted their price objective on Iqvia from $128.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 25th. Raymond James upgraded Iqvia from an “outperform” rating to a “strong-buy” rating in a report on Tuesday, July 3rd. Mizuho set a $120.00 price objective on Iqvia and gave the stock a “hold” rating in a report on Monday, August 6th. Finally, Wells Fargo & Co lifted their price objective on Iqvia from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Monday, August 13th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Iqvia currently has an average rating of “Buy” and an average target price of $126.79.

In other news, insider Ari Bousbib sold 368,640 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The stock was sold at an average price of $122.09, for a total transaction of $45,007,257.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert Parks sold 871 shares of the business’s stock in a transaction that occurred on Thursday, August 2nd. The stock was sold at an average price of $124.34, for a total value of $108,300.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 978,777 shares of company stock worth $121,566,089. Insiders own 6.00% of the company’s stock.

Shares of Iqvia stock traded up $0.08 on Friday, hitting $126.59. 555,291 shares of the company were exchanged, compared to its average volume of 953,631. The stock has a market cap of $25.35 billion, a P/E ratio of 29.03, a P/E/G ratio of 1.80 and a beta of 0.70. Iqvia Holdings Inc has a 1-year low of $91.57 and a 1-year high of $128.40. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.13 and a quick ratio of 1.13.

Iqvia (NYSE:IQV) last issued its earnings results on Tuesday, July 24th. The medical research company reported $1.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The business had revenue of $2.57 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. research analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Understanding Analyst Recommendations

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.